Analysis of molecular mechanisms of delafloxacin resistance in Escherichia coli [PDF]
Scientific ReportsIn this study delafloxacin resistance mechanisms in Escherichia coli strains were analyzed. Delafloxacin is a new fluoroquinolone, that is approved for clinical application however, resistance against this agent is scarcely reported.
András Kubicskó +3 more
doaj +4 more sources
Genetic Mechanisms of Antimicrobial Non-Susceptibility to Novel Fluoroquinolone Delafloxacin Among Bulgarian Clinical Isolates of Streptococcus agalactiae [PDF]
Current Issues in Molecular BiologyDelafloxacin is one of the newest fluoroquinolones with a unique structure, determining better pharmacokinetic and pharmacodynamic properties, a better safety profile, and a broader spectrum of activity compared to older quinolones.
Vasil Boyanov +2 more
doaj +3 more sources
Updated Review on Clinically-Relevant Properties of Delafloxacin
Antibiotics, 2023 The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds.
Adrien Turban +3 more
doaj +4 more sources
Delafloxacin: A Review in Community-Acquired Pneumonia
Drugs, 2022 Delafloxacin (BAXDELA® in the USA; Quofenix® in the EU) is an anionic fluoroquinolone antibacterial that is approved for the treatment of community-acquired pneumonia (CAP) and acute bacterial skin and skin structure infections in adults. Delafloxacin demonstrated in vitro activity against Gram-positive and Gram-negative pathogens, including drug ...
Arnold Lee, Yvette N. Lamb, Matt Shirley
openaire +3 more sources
Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment [PDF]
The Journal of Clinical Pharmacology, 2016 AbstractDelafloxacin is a novel anionic fluoroquinolone with robust activity against Gram‐positive, Gram‐negative, atypical, and anaerobic bacteria, including methicillin‐resistant S aureus. Delafloxacin is currently being studied for the treatment of acute bacterial skin and skin structure infections and community‐acquired pneumonia.
Hoover, Randall +7 more
openaire +3 more sources
Investigation of Delafloxacin Resistance in Multidrug-Resistant Escherichia coli Strains and the Detection of E. coli ST43 International High-Risk Clone [PDF]
Microorganisms, 2023 Delafloxacin is a novel fluoroquinolone agent that is approved for clinical application. In this study, we analyzed the antibacterial efficacy of delafloxacin in a collection of 47 Escherichia coli strains.
Dániel Gulyás +3 more
doaj +2 more sources
A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections [PDF]
International Journal of Infectious Diseases, 2015 Background: A randomized, double-blind, multicenter trial was done to compare two doses of delafloxacin with tigecycline in patients with various complicated skin and skin-structure infections (wound infections following surgery, trauma, burns, or animal/
William O’Riordan +5 more
doaj +2 more sources
Delafloxacin for the treatment of respiratory and skin infections
Expert Opinion on Investigational Drugs, 2015 There has been a striking increase in the emergence of multidrug-resistant pathogens in recent times. Delafloxacin is a novel, broad-spectrum fluoroquinolone with antimicrobial activity against resistant Gram-positive, Gram-negative and anaerobic organisms.
BASSETTI, MATTEO +4 more
openaire +5 more sources
Effect of pH on antimicrobial activity of delafloxacin against Escherichia coli isogenic strains carrying diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms [PDF]
Microbiology SpectrumThe aim of this study is to evaluate the pH-dependent antimicrobial activities of delafloxacin against isogenic Escherichia coli strains carrying diverse fluoroquinolone resistance mechanisms. Eighty-one isogenic E.
K. Alexandre +4 more
doaj +2 more sources
Delafloxacin: what does a new fluoroquinolone offer? [PDF]
Rev Esp QuimioterDelafloxacin is a novel anionic fluoroquinolone with a different chemical structure from currently marketed fluoroquinolones, which gives it distinct physicochemical characteristics, being active in both acidic and neutral environments. Delafloxacin is also unique in showing a dual-targeted equipotent inhibition of the essential bacterial enzymes DNA ...
Cercenado E, Murillo O.
europepmc +4 more sources